NPY methylated ctDNA is a promising biomarker for treatment response monitoring in metastatic colorectal cancer. Janssens K, Vanhoutte G, Lybaert W, Demey W, et al. Clin Cancer Res 2023 Jan 30:CCR-22-1500. doi: 10.1158/1078-0432.CCR-22-1500.

Read + Share

Amedeo Smart

Independent Medical Education

Janssens K, Vanhoutte G, Lybaert W, Demey W, et al. NPY methylated ctDNA is a promising biomarker for treatment response monitoring in metastatic colorectal cancer. Clin Cancer Res 2023 Jan 30:CCR-22-1500. doi: 10.1158/1078-0432.CCR-22-1500.
PMID: 36716292